← Back to patent-cliff list
CAS 2549-14-6
(R)-2-amino-1-phenylethanol
Codes：MIRA-019
Application context (from source-drug indications)
神经性膀胱功能障碍米拉贝隆膀胱过度活动症米拉贝隆
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| 米拉贝隆Mirabegron | Tier B — Position early | 2029 |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
2-(2-aminothiazol-4-yl)acetic acid→(R)-2-((4-aminophenethyl)amino)-1-phenylethan-1-ol→2-(4-aminophenyl)ethanol→tert-butyl (4-(2-hydroxyethyl)phenyl)carbamate→tert-butyl (4-(2-oxoethyl)phenyl)carbamate→(R)-2-amino-1-phenylethanol→tert-butyl (R)-(4-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)carbamate
(R)-2-amino-1-phenylethanol→2-(2-aminothiazol-4-yl)acetic acid hydrochloride→2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetic acid→2-(2-(benzylamino)thiazol-4-yl)acetic acid→2-(2-((ethoxycarbonyl)amino)thiazol-4-yl)acetic acid→4-(2-bromoethyl)aniline hydrochloride→4-(2-chloroethyl)aniline hydrochloride→tert-butyl (4-(2-((4-(2-bromoethyl)phenyl)amino)-2-oxoethyl)thiazol-2-yl)carbamate→2-(2-(benzylamino)thiazol-4-yl)-N-(4-(2-bromoethyl)phenyl)acetamide→ethyl (4-(2-((4-(2-chloroethyl)phenyl)amino)-2-oxoethyl)thiazol-2-yl)carbamate→tert-butyl (4-(2-((4-(2-chloroethyl)phenyl)amino)-2-oxoethyl)thiazol-2-yl)carbamate→tert-butyl (R)-(4-(2-((4-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)amino)-2-oxoethyl)thiazol-2-yl)carbamate→(R)-2-(2-(benzylamino)thiazol-4-yl)-N-(4-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)acetamide→ethyl (R)-(4-(2-((4-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)amino)-2-oxoethyl)thiazol-2-yl)carbamate
2-(4-aminophenyl)ethanol→(R)-2-amino-1-phenylethanol→2-(2-aminothiazol-4-yl)acetic acid hydrochloride→2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetic acid→tert-butyl (R)-(4-(2-((4-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)amino)-2-oxoethyl)thiazol-2-yl)carbamate→2-(2-(((benzyloxy)carbonyl)amino)thiazol-4-yl)acetic acid→2-(2-(tritylamino)thiazol-4-yl)acetic acid→tert-butyl (4-(2-((4-(2-hydroxyethyl)phenyl)amino)-2-oxoethyl)thiazol-2-yl)carbamate→benzyl (4-(2-((4-(2-hydroxyethyl)phenyl)amino)-2-oxoethyl)thiazol-2-yl)carbamate→N-(4-(2-hydroxyethyl)phenyl)-2-(2-(tritylamino)thiazol-4-yl)acetamide→tert-butyl (4-(2-oxo-2-((4-(2-oxoethyl)phenyl)amino)ethyl)thiazol-2-yl)carbamate→benzyl (4-(2-oxo-2-((4-(2-oxoethyl)phenyl)amino)ethyl)thiazol-2-yl)carbamate→N-(4-(2-oxoethyl)phenyl)-2-(2-(tritylamino)thiazol-4-yl)acetamide→benzyl (R)-(4-(2-((4-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)amino)-2-oxoethyl)thiazol-2-yl)carbamate→(R)-2-(2-((l1-phosphanyl)amino)thiazol-4-yl)-N-(4-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)acetamide
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.